DHL Global Forwarding has added six dedicated healthcare air cargo corridors connecting Europe and North America with pharmaceutical markets across Asia — but the company has not disclosed the freight capacity or weekly flight frequencies behind them, which limits what shippers can actually plan around.

The new routes link Liège with Shanghai; Brussels with Shanghai and Singapore; and Cincinnati with Singapore, Tokyo Narita and Seoul Incheon. All six sit inside DHL Health Logistics' Cold Chain Network, the division that pairs dedicated healthcare lanes with temperature-controlled infrastructure and specialised handling procedures.

They follow a Brussels–Cincinnati healthcare corridor introduced earlier this year, meaning DHL has now launched seven pharma-specific air lanes in a single calendar year.

What changes for pharmaceutical shippers?

The commercial pitch is control. Most flights supporting the corridors operate within DHL's own air network, which reduces the number of cargo handovers — each handover being a point where temperature excursions typically occur — and gives the forwarder greater oversight of shipment conditions.

The hardware matters as much as the routing. DHL flies Boeing 777 freighters with three compartments that can be configured for different temperature requirements, and the network adds thermal blankets and validated handling procedures to limit temperature exposure during transfers.

For shippers moving vaccines, biologics and clinical trial materials, the practical gain is additional routing options and access to guaranteed temperature-controlled air freight capacity on lanes where such capacity has historically been stitched together from passenger bellyhold space and third-party charters. Forwarders competing for pharma contracts will now face a carrier with named, dedicated lanes rather than ad hoc solutions.

"These new corridors further expand our Cold Chain Network into strategically important healthcare markets across Asia," said Henk Venema, Global Head of Air Freight at DHL Global Forwarding.

How deep is the commitment?

The capacity question is the one DHL left unanswered. The company said the corridors will support more reliable transportation of sensitive healthcare products while reducing supply chain risks, but it has not disclosed additional freight capacity figures or weekly flight frequencies for any of the six routes. Until those numbers surface, the scale of the expansion remains a routing announcement rather than a measurable capacity injection.

The infrastructure spending, by contrast, is concrete and specific:

• A new Singapore Cold Chain Hub under development, with temperature-controlled storage operating at 2–8°C and 15–25°C, plus direct airside access.
• Expansion of the life sciences and healthcare facility in Indianapolis, adding refrigerated operational and pallet storage space.
• The Brussels–Singapore and Cincinnati–Singapore corridors, which DHL says reinforce Singapore's role as its Asia-Pacific healthcare gateway.

Cincinnati, meanwhile, retains its position as the North American anchor, now feeding three Asian destinations directly: Singapore, Tokyo Narita and Seoul Incheon.

Why pharma cold chain is the battleground

Temperature-sensitive healthcare cargo — pharmaceuticals, vaccines, biologics and clinical trial materials — commands premium rates and long-term contracts, which is why forwarders keep investing in dedicated networks rather than relying on general cargo capacity. Every avoided cargo handover reduces both spoilage risk and insurance exposure, and validated handling procedures are increasingly a precondition for winning large pharma tenders.

For competing forwarders, the move raises the bar: DHL now offers named corridors into every major North Asian pharma market plus a Singapore hub with direct airside access under construction. For airlines selling bellyhold space, dedicated freighter corridors on these lanes could divert pharma volumes that previously rode in passenger aircraft holds.

The unanswered capacity question cuts both ways. If DHL backfills the corridors with meaningful freighter frequencies, the pharma air freight market on Europe–Asia and transpacific lanes tightens further. If the lanes run thin, competitors have room to argue the network is broader than it is deep. Watch for flight schedules and tonnage disclosures as the Singapore hub comes online.